Combining Niraparib with Abiraterone Acetate and Prednisone Significantly Improves rPFS in Patients with mCSPC Harbouring BRCA1/2 or Other HRR Gene Alterations By Ogkologos - October 22, 2025 251 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AMPLITUDE study Source RELATED ARTICLESMORE FROM AUTHOR High HPV Vaccination Coverage in England Associated with a Substantial Reduction in Cervical Cancer Mortality FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic TNBC Oral Sunvozertinib Prolongs PFS Over Chemotherapy as First-Line Treatment for Patients with Advanced NSCLC with EGFR Exon 20 Insertions MOST POPULAR How Exercise Can Help You Cope With the Mental and Emotional... August 18, 2022 KRASG12 Mutations Are Biomarkers for Reduced Overall Survival Benefit of Treatment... March 14, 2023 Robust and Sustained Survival Benefit with Consolidation Durvalumab After Concurrent Chemoradiotherapy... February 8, 2022 Real-World Increase in Biomarker Testing in Lung Cancer Patients, Registry Study... March 23, 2022 Load more HOT NEWS ASCO Annual Meeting 2023: Trastuzumab Deruxtecan Effectively Treats HER2-Expressing Tumors and... Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active... Satisfying Snacks Stressed out – the cancer cells that survive chemotherapy, but at...
